Evidence map›Paper›PMID 39156147›Full record

ArticleKidney international reports2024

Voclosporin Induces Systemic Lipidomic Alterations: Implications for Lupus Nephritis Remission.

Farsad Afshinnia, Thekkelnaycke M Rajendiran, Jaeman Byun, Manikanta Swamy Arnipalli, Linda M Rehaume, Jennifer L Cross, Robert B Huizinga, Subramaniam Pennathur

Abstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Farsad AfshinniaDepartment of Internal Medicine-Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Thekkelnaycke M RajendiranMichigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA.
Jaeman ByunDepartment of Internal Medicine-Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Manikanta Swamy ArnipalliDepartment of Internal Medicine-Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Linda M RehaumeAurinia Pharmaceuticals Inc., Edmonton, Alberta, Canada.
Jennifer L CrossAurinia Pharmaceuticals Inc., Edmonton, Alberta, Canada.
Robert B HuizingaReformation Consulting Services Inc., Victoria, BC, Canada.
Subramaniam PennathurDepartment of Internal Medicine-Nephrology, University of Michigan, Ann Arbor, Michigan, USA.

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
University of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C · 2008 to 2022
$12.9M
University of Michigan O'Brien Kidney Translational Resource Center (MKTC)U54DK137314 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Subramaniam Pennathur · 2023 to 2026
$4.7M
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK081943NIDDK NIH HHS P30 DK089503NIDDK NIH HHS U54 DK137314
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiovascular risklipidomicslupus nephritismediation analysisremissionvoclosporin

Identifiers

PMID39156147
PMCPMC11328555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.